Company Announcements
Director/PDMR Shareholding
Related Companies
By LSE RNS
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")
6 June 2017
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
Vesting of awards under the Company's Forfeitable Share Plan
The awards of ordinary shares in Mediclinic (the "Shares") set out in the table below, granted on 31 July 2014, vested under the Company's Forfeitable Share Plan on 31 May 2017.
|
Name |
Director/ PDMR |
Number of Shares vested |
Number of Shares sold at ZAR 130.44 per share |
Number of Shares retained1 |
|
Danie Meintjes |
Director |
49,423 |
0 |
49,423 |
|
Gert Hattingh |
PDMR |
14,734 |
0 |
14,734 |
|
Koert Pretorius |
PDMR |
19,806 |
19,806 |
0 |
|
David Hadley |
PDMR |
9,778 |
9,778 |
0 |
|
Dr Ole Wiesinger1 |
PDMR |
17,506 |
0 |
17,506 |
|
Dr Ronnie van der Merwe |
PDMR |
16,507 |
16,507 |
0 |
1. Dr Wiesinger was granted a conditional right to 17,506 Shares under the Country Schedule to the Forfeitable Share Plan on 31 July 2014. On 1 June 2017, Dr Wiesinger elected to receive the award in Shares, which he received on 5 June 2017.
The following notification made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation relates to the Company's Forfeitable Share Plan.
|
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||
|
a) |
Name |
Daniël Petrus Meintjes
|
||||
|
2. |
Reason for the notification
|
|||||
|
a) |
Position / status |
Chief Executive Officer of the Company
|
||||
|
b) |
Initial notification / amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Mediclinic International plc
|
||||
|
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares
GB00B8HX8Z88
|
||||
|
b) |
Nature of the transaction |
Vesting of award over 49,423 ordinary shares awarded under the Company's Forfeitable Share Plan
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume
Price |
49,423
Nil cost
|
||||
|
e) |
Date of the transaction |
1 June 2017
|
||||
|
f) |
Place of the transaction |
Johannesburg Stock Exchange |
||||
|
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||
|
a) |
Name |
Gert C Hattingh
|
||||
|
2. |
Reason for the notification
|
|||||
|
a) |
Position / status |
Chief Corporate Services Officer of the Company
|
||||
|
b) |
Initial notification / amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Mediclinic International plc
|
||||
|
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares
GB00B8HX8Z88
|
||||
|
b) |
Nature of the transaction |
Vesting of award over 14,734 ordinary shares awarded under the Company's Forfeitable Share Plan
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume
Price |
14,734
Nil cost
|
||||
|
e) |
Date of the transaction |
1 June 2017
|
||||
|
f) |
Place of the transaction |
Johannesburg Stock Exchange |
||||
|
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||||
|
a) |
Name |
Koert Hendrik S Pretorius
|
||||||
|
2. |
Reason for the notification
|
|||||||
|
a) |
Position / status |
Chief Executive Officer - Mediclinic Southern Africa
|
||||||
|
b) |
Initial notification / amendment |
Initial Notification
|
||||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
Mediclinic International plc
|
||||||
|
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares
GB00B8HX8Z88
|
||||||
|
b) |
Nature of the transaction |
1. Vesting of award over 19,806 ordinary shares awarded under the Company's Forfeitable Share Plan
2. Sale of 19,806 ordinary shares.
|
||||||
|
c) |
Price(s) and volume(s) |
|
||||||
|
d) |
Aggregated information
Aggregated volume
Price |
1. 19,806 2. 19,806
1. Nil cost 2. ZAR 130.44
|
||||||
|
e) |
Date of the transaction |
1 June 2017
|
||||||
|
f) |
Place of the transaction |
Johannesburg Stock Exchange |
||||||
|
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||||
|
a) |
Name |
David J Hadley
|
||||||
|
2. |
Reason for the notification
|
|||||||
|
a) |
Position / status |
Chief Executive Officer - Mediclinic Middle East
|
||||||
|
b) |
Initial notification / amendment |
Initial Notification
|
||||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
Mediclinic International plc
|
||||||
|
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares
GB00B8HX8Z88
|
||||||
|
b) |
Nature of the transaction |
1. Vesting of award over 9,778 ordinary shares awarded under the Company's Forfeitable Share Plan
2. Sale of 9,778 ordinary shares.
|
||||||
|
c) |
Price(s) and volume(s) |
|
||||||
|
d) |
Aggregated information
Aggregated volume
Price |
1. 9,778 2. 9,778
1. Nil cost 2. ZAR 130.44
|
||||||
|
e) |
Date of the transaction |
1 June 2017
|
||||||
|
f) |
Place of the transaction |
Johannesburg Stock Exchange |
||||||
|
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||
|
a) |
Name |
Dr Thorsten Ole Wiesinger
|
||||
|
2. |
Reason for the notification
|
|||||
|
a) |
Position / status |
Chief Executive Officer - Hirslanden
|
||||
|
b) |
Initial notification / amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Mediclinic International plc
|
||||
|
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares
GB00B8HX8Z88
|
||||
|
b) |
Nature of the transaction |
Vesting of conditional right to 17,506 Shares under the Country Schedule to the Forfeitable Share Plan on 31 July 2014
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume
Price |
17,506
Nil cost
|
||||
|
e) |
Date of the transaction |
5 June 2017
|
||||
|
f) |
Place of the transaction |
Johannesburg Stock Exchange |
||||
|
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||||
|
a) |
Name |
Dr Carel A van der Merwe
|
||||||
|
2. |
Reason for the notification
|
|||||||
|
a) |
Position / status |
Chief Clinical Officer of the Company
|
||||||
|
b) |
Initial notification / amendment |
Initial Notification
|
||||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
Mediclinic International plc
|
||||||
|
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares
GB00B8HX8Z88
|
||||||
|
b) |
Nature of the transaction |
1. Vesting of award over 16,507 ordinary shares awarded under the Company's Forfeitable Share Plan
2. Sale of 16,507 ordinary shares.
|
||||||
|
c) |
Price(s) and volume(s) |
|
||||||
|
d) |
Aggregated information
Aggregated volume
Price |
1. 16,507 2. 16,507
1. Nil cost 2. ZAR 130.44
|
||||||
|
e) |
Date of the transaction |
1 June 2017
|
||||||
|
f) |
Place of the transaction |
Johannesburg Stock Exchange |
||||||
About Mediclinic International plc
Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.
Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with more than 1 600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with more than 700 inpatient beds in the United Arab Emirates.
During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.
Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.
For further information, please contact:
Capita Company Secretarial Services Limited
Victoria Dalby
+44 (0)207 954 9600
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott (UK)
+44 (0)20 3727 1000
Frank Ford (South Africa)
+27 (0)21 487 9000
Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
This information is provided by RNS
You are here: news > regulatory news
10 Lower Thames St,
London EC3R 6EN